background
new
promis
therapeut
approach
emerg
patient
chronic
infect
hepat
b
viru
hbv
develop
nonrepl
adenoviru
vector
vaccin
candid
adhbv
vaccin
encod
fusion
protein
compos
truncat
hbv
core
protein
mutat
polymeras
protein
two
envelop
domain
studi
assess
immunogen
adhbv
administ
cynomolgu
monkey
nonclin
safeti
assess
method
viru
subcutan
administ
viral
particl
vp
anim
lowdos
group
vpanim
middos
group
vpanim
highdos
group
control
group
administ
viru
vpanim
salin
result
except
inflammatori
cell
infiltr
skin
inject
site
transient
elev
bodi
temperatur
serum
albumin
adhbvrel
toxic
effect
note
treatment
group
moreov
interferon
ifn
enzymelink
immunospot
assay
show
adhbv
induc
target
cell
broad
spectrum
hbvspecif
epitop
span
three
select
hbv
immunogen
core
polymeras
envelop
domain
dosedepend
manner
although
antiad
antibodi
produc
group
except
salin
control
antibodi
titer
significantli
lower
highdos
adhbv
group
group
receiv
dose
adnul
empti
vector
addit
express
level
liver
significantli
improv
middos
highdos
adnul
control
group
p
lowdos
group
conclus
taken
togeth
safeti
assess
indic
adhbv
candid
vaccin
potent
specif
immunotherapeut
agent
support
clinic
develop
antihbv
infect
vaccin
hepat
b
viru
hbv
infect
continu
seriou
clinic
challeng
induc
develop
liver
cirrhosi
hepatocellular
carcinoma
even
lead
mortal
mani
area
world
current
util
firstlin
antivir
agent
immun
system
modul
recommend
world
health
organ
help
reduc
control
viral
load
minim
liver
damag
effect
clear
infect
seldom
achiev
cure
thu
current
therapi
remain
far
satisfactori
particular
wide
spread
multidrugresist
hbv
strain
increasingli
threaten
efficaci
current
avail
antivir
drug
therefor
urgent
need
activ
develop
test
promis
novel
therapi
target
hbv
gene
therapi
consid
newli
effect
option
mani
diseas
directli
deliv
therapeut
gene
induc
improv
system
immun
respons
owe
effici
infect
high
load
capac
stabil
outsid
cell
adenoviru
ad
promis
candid
vector
gene
deliveri
wide
adopt
mani
gene
therapi
strategi
develop
date
adhbv
consid
primari
hbv
immunotherapeut
develop
transgenet
approach
aim
applic
treat
patient
chronic
infect
hbv
adhbv
therapeut
vaccin
candid
base
human
replicationdefect
ad
serotyp
vector
encod
hbv
fusion
protein
consist
truncat
form
hbv
core
domain
ntermin
fuse
delet
mutat
hbv
polymeras
sequenc
two
hbv
envelop
domain
insert
within
polymeras
delet
nucleotid
sequenc
encod
hbv
fusion
protein
base
hbv
isol
slightli
modifi
vaccin
candid
design
stimul
specif
cellbas
immun
similar
seen
hbv
resolv
pharmacodynam
studi
adhbv
perform
three
anim
model
thu
far
transgen
mice
mice
balbc
mice
case
adhbv
demonstr
effect
induc
cell
produc
variou
cytokin
interferon
ifn
tumor
necrosi
factor
tnf
interleukin
il
respons
hbv
antigen
stimul
howev
potenti
disadvantag
note
includ
damag
host
immun
respons
hepatocytox
short
halflif
thu
nonclin
safeti
assess
essenti
prior
clinic
develop
trial
vaccin
unsolv
challeng
develop
gene
therapi
drug
vector
encod
protein
ultim
becom
immunogen
patient
therebi
provok
immun
respons
result
immunotox
contrast
therapeut
protein
whose
immunogen
mainli
evalu
measur
level
antidrug
antibodi
produc
current
wellestablish
wide
accept
method
immunogen
assess
gene
therapi
drug
therefor
present
studi
focus
evalu
immunogen
subcutan
inject
adshbv
vaccin
nonhuman
primat
differ
dose
obtain
refer
data
nonclin
safeti
assess
prepar
clinic
trial
human
lung
cancer
cell
line
purchas
shanghai
cell
resourc
center
chines
academi
cultur
dulbecco
modifi
eagl
medium
dmem
thermo
fisher
biochem
product
beij
china
supplement
antibiot
uml
penicillin
mgml
streptomycin
invitrogen
life
technolog
fetal
bovin
serum
gibco
life
technolog
co
incub
ad
vector
use
studi
includ
encod
antigen
empti
ad
hereaft
adnul
adhbv
construct
produc
purifi
titrat
describ
elsewher
final
purifi
virus
resuspend
steril
phosphatebuff
salin
pb
buffer
store
viru
quantif
number
viru
particl
vp
determin
highpressur
liquid
chromatographi
longterm
toxic
adhbv
vaccin
evalu
b
virusand
adfre
cynomolgu
monkey
macaca
fasciculari
nonhuman
primat
model
present
safeti
assess
obtain
hainan
new
sourc
biotech
co
ltd
hainan
china
total
monkey
use
studi
equal
number
male
femal
weigh
kg
brief
monkey
divid
five
group
n
per
group
five
anim
per
sex
inject
adhbv
follow
dose
vpanim
lowdos
group
vpanim
middos
group
vpanim
highdos
group
vehicl
control
ml
salin
per
anim
inject
vpanim
use
control
anim
inject
subcutan
weekli
seven
time
total
anim
clinic
symptom
continu
observ
twice
day
month
gene
therapi
day
last
dose
six
anim
group
three
anim
per
sex
sacrif
safeti
toxicolog
biodistribut
analys
remain
anim
left
recov
week
monitor
paramet
collect
anim
sever
time
point
time
schedul
experiment
protocol
summar
tabl
evalu
immunoreact
adhbv
lymphocyt
subgroup
peripher
blood
analyz
throughout
trial
flow
cytometri
assay
peripher
blood
lymphocyt
anim
isol
use
lymphocyt
separ
medium
tbdscienc
tianjin
china
densitygradi
centrifug
accord
manufactur
instruct
cell
stain
specif
conjug
antibodi
subject
flow
cytometri
respect
data
analyz
use
flowjo
softwar
ihc
use
determin
express
liver
tissu
collect
anim
group
brief
paraffinembed
tissu
prepar
sacrif
anim
section
liver
tissu
prepar
extract
paraffin
xylen
section
rehydr
endogen
peroxidas
inactiv
h
pb
section
treat
antigen
repair
solut
mm
citrat
solut
maixinbio
fujian
china
microwav
oven
min
retriev
antigen
block
nonspecif
reactiv
bovin
serum
albumin
section
incub
antibodi
monkey
abcam
abcam
biolegend
h
wash
three
time
pb
suitabl
secondari
antibodi
label
horseradish
peroxidas
hrp
ad
section
incub
h
slide
wash
five
time
pb
develop
use
diaminobenzidin
kit
maixinbio
fujian
china
accord
manufactur
instruct
immunoreact
grade
follow
four
group
base
frequenc
posit
stain
neg
specif
stain
posit
stain
posit
stain
posit
stain
posit
stain
grade
consid
reflect
low
express
grade
consid
reflect
high
express
quantiti
cell
peripher
blood
trial
assess
elispot
use
monkey
kit
mabtech
inc
cincinnati
oh
usa
follow
manufactur
instruct
peptid
use
studi
tabl
previous
identifi
show
reactiv
pilot
experi
cynomolgu
monkey
synthes
genscript
biolog
technolog
co
ltd
nanj
china
librari
peptid
dissolv
dimethyl
sulfoxid
dmso
sigma
pool
concentr
mgml
per
peptid
pool
test
final
concentr
per
peptid
elispot
assay
three
peptid
pool
use
stimulatori
agent
henc
elispot
assay
carri
five
group
includ
neg
control
unrel
peptid
dmso
dlmdlmgyiplv
core
pool
env
pool
pol
pool
posit
control
igg
provid
kit
brief
approxim
ml
peripher
blood
collect
isol
lymphocyt
sampl
tube
heparin
lymphocyt
well
triplic
plate
incub
complet
dmem
contain
differ
peptid
control
agent
h
humidifi
incub
co
medium
remov
plate
wash
five
time
pb
hrpconjug
ad
well
plate
wash
five
time
pb
incub
h
room
temperatur
final
tmb
substrat
solut
use
detect
spot
plate
dri
spot
well
inspect
count
dissect
microscop
antiadhbv
antibodi
titer
measur
indirect
enzymelink
immunosorb
assay
ielisa
previous
describ
brief
bind
antidrug
antibodi
serum
sampl
precoat
inactiv
antigen
microtit
plate
vp
carbonatebicarbon
buffer
per
well
detect
hrplabel
antimonkey
immunoglobulin
g
igg
base
cutoff
point
optic
densiti
valu
nm
posit
neg
preadministr
serum
sampl
anim
screen
neutral
activ
measur
use
adapt
luciferasebas
viru
neutral
assay
brief
dilut
serum
sampl
mix
vp
complet
dmem
luciferaseexpress
ad
vector
shenzhao
biotechnolog
china
incub
h
room
temperatur
cell
ad
medium
incub
co
h
luciferas
assay
system
promega
use
measur
luciferas
activ
cell
micropl
reader
biotek
final
neutral
antibodi
activ
blood
anim
administr
evalu
accord
follow
formula
neutral
effici
mean
fluoresc
intens
preadministr
control
group
mean
fluoresc
intens
administr
group
mean
fluoresc
intens
preadministr
control
group
data
present
mean
standard
deviat
group
analyz
use
spss
softwar
packet
comparison
group
test
oneway
anova
measur
data
analyz
chisquar
test
rank
data
analyz
fisher
exact
probabl
data
dose
group
compar
vehicl
control
group
p
deem
reflect
statist
signific
differ
erythema
observ
inject
site
skin
differ
proport
anim
adhbv
group
lowdos
middos
highdos
group
detect
vehicl
control
group
histolog
examin
show
infiltr
inflammatori
cell
plasma
cell
lymphocyt
skin
inject
site
repres
local
immun
respons
caus
administr
ad
vector
fig
compar
vehicl
control
group
transient
elev
alb
day
tp
day
level
detect
along
increas
bodi
temperatur
day
adhbv
adnul
group
inject
howev
level
chang
substanti
vector
administr
fluctuat
within
normal
physiolog
rang
addit
file
tabl
addit
file
tabl
addit
file
tabl
thu
effect
reflect
signific
toxicolog
reaction
compar
vehicl
control
group
signific
differ
lymphocyt
subset
detect
cell
lowdos
group
macrophag
adnul
group
howev
chang
note
singl
index
dosedepend
indic
minim
biolog
signific
paramet
fluctuat
within
normal
rang
throughout
studi
addit
file
tabl
addit
throughout
cours
studi
signific
differ
observ
bodi
weight
overal
find
demonstr
main
toxic
adhbv
relat
stimul
inject
site
ad
confirm
potent
function
cellular
immun
respons
nonhuman
primat
result
adhbv
inject
nonclin
safeti
assess
monitor
hbvspecif
immun
respons
use
elispot
assay
although
number
hbv
antigen
core
env
pol
specif
cell
peripher
blood
mononuclear
cell
pbmc
significantli
higher
three
dose
group
low
mid
high
compar
vehicl
control
group
control
group
p
day
cell
number
lowdos
group
vpanim
significantli
lower
p
middos
vpanim
highdos
vp
anim
group
fig
addit
although
number
hbv
antigenspecif
cell
pbmc
middos
group
significantli
lower
highdos
group
first
administr
day
p
differ
group
day
result
indic
dose
set
toxic
assess
test
reason
vp
anim
highest
effect
dose
adhbv
test
cynomolgu
macaqu
bind
neutral
activ
antidrug
antibodi
ad
vectorbas
vaccin
may
affect
clinic
efficaci
alter
pharmacokinet
profil
caus
advers
effect
therefor
use
antiad
antibodyneg
anim
nonclin
safeti
assess
test
monitor
level
antiad
antibodi
serum
adhbv
administr
level
antiad
antibodi
dosedepend
increas
administr
adhbv
reach
peak
valu
day
sustain
last
administr
day
level
antiad
antibodi
control
group
ad
empti
vector
vpanim
higher
detect
anim
receiv
samedos
highdos
vp
anim
adhbv
group
may
result
gene
insert
truncat
pol
core
env
antigen
addit
antibodi
titer
sustain
higher
level
week
recoveri
day
fig
neutral
activ
highesttit
serum
sampl
everi
anim
control
group
three
adhbv
group
low
mid
high
dose
measur
ad
vector
luciferaseexpress
inhibit
assay
h
infect
fluoresc
intens
cell
gradient
increas
proport
concentr
improv
sensit
sensit
model
select
vpml
infect
cell
neutral
experi
compar
predos
serum
sampl
dilut
serum
sampl
cynomolgu
monkey
inject
subcutan
low
dose
vpanim
mid
dose
vpanim
high
dose
vpanim
adhbv
empti
adnul
vector
vp
anim
equal
volum
salin
inject
neg
control
hbv
antigenspecif
cell
monitor
quantifi
elispot
assay
conduct
day
b
c
postinject
use
peripher
blood
mononuclear
cell
pbmc
respect
stimul
hbv
peptid
pool
core
env
irrelev
peptid
dlm
p
p
vs
vehicl
control
antidrug
antibodyposit
anim
decreas
fluoresc
intens
differ
extent
infect
cell
serum
neutral
effect
highdos
adnul
group
significantli
higher
lowdos
middos
group
indic
antidrug
antibodyposit
serum
inhibit
infect
activ
neutral
activ
dosedepend
fig
thu
although
antiad
antibodi
produc
almost
anim
first
immun
antibodi
could
partial
neutral
abil
ad
infect
sinc
ad
vector
predominantli
sequest
liver
administr
previou
studi
reveal
ad
infect
could
significantli
improv
express
antivir
immun
cytokin
analyz
level
protein
liver
ihc
explor
immun
respons
strategi
liver
shown
tabl
fig
administr
adhbv
significantli
improv
express
level
liver
middos
highdos
adnul
control
group
p
lowdos
group
suggest
increas
express
two
cytokin
liver
relat
amount
ad
vector
inject
howev
correl
express
administr
adhbv
sever
studi
conduct
applic
gene
therapi
use
vaccin
treatment
cancer
chronic
viru
infect
shown
immunogen
respons
specif
ad
protein
transgeneencod
protein
induc
vaccin
could
signific
impact
efficaci
recombin
ad
vaccin
thu
essenti
aspect
ensur
efficaci
virusvector
drug
comprehens
accur
evalu
immunogen
evalu
basic
immunogen
characterist
adhbv
vaccin
monitor
induc
hbvspecif
cell
respons
glp
threemonth
repeat
dose
toxic
studi
use
cynomolgu
monkey
nonhuman
primat
model
gener
new
extensivelyaccept
therapi
option
major
toxicolog
effect
observ
possibl
associ
activ
immun
respons
induc
adhbv
exampl
erythema
inject
point
skin
abnorm
peripher
blood
lymphocyt
subset
although
transient
increas
physiolog
paramet
wbc
crea
tp
alb
et
al
compar
vehicl
control
group
valu
still
within
normal
rang
toxicolog
signific
compar
vehicl
control
group
signific
p
p
paramet
cell
lowdos
middos
group
differ
day
mostli
chang
singl
index
dose
depend
biolog
signific
although
antiadenoviru
antibodi
produc
almost
anim
first
immun
cutoff
titer
valu
antibodi
titer
group
respect
shown
purpl
control
green
highdos
group
red
middos
group
blue
lowdos
group
curv
antibodi
titer
compar
use
nonparametr
test
friedman
test
dunn
multipl
comparison
test
p
valu
fig
neutral
cell
luciferaseexpress
adenoviru
neutral
determin
transgen
express
inhibit
cell
pretreat
mix
serum
differ
dilut
neutral
effici
calcul
triplic
measur
quadrat
measur
shown
viral
particl
vp
cell
per
well
p
p
antibodi
could
partial
neutral
abil
adenoviru
infect
adhbv
still
induc
strong
broad
cell
respons
display
whole
array
immunogen
characterist
show
highli
immunogen
potenti
adhbv
vaccin
adenoviru
vector
predominantli
sequest
liver
administr
analyz
level
protein
live
immunochemistri
assay
found
two
antivir
cytokin
highdos
control
group
higher
express
vehicl
control
group
current
studi
sever
limit
first
natur
killer
nk
cell
natur
enrich
liver
hbv
infect
adenoviru
vector
deliveri
affect
function
nk
cell
howev
properli
evalu
function
nk
cell
studi
addit
note
investig
cell
target
hbv
antigensdomain
encod
adhbv
produc
antivir
cytokin
overal
nonclin
safeti
assess
show
adhbv
immunotherapeut
product
induc
biolog
signific
toxic
induc
strong
broad
cell
respons
display
whole
array
immunogen
characterist
demonstr
high
immunogen
potenti
adhbv
vaccin
moreov
candid
vaccin
advantag
gather
three
hbv
antigen
one
vector
togeth
capac
induc
potent
antivir
respons
broad
immunogen
characterist
thu
adhbv
select
lead
candid
clinic
develop
high
low
high
p
compar
vehicl
control
lowdos
group
respect
fig
repres
imag
posit
immunohistochem
stain
cynomolgu
monkey
liver
tissu
imag
taken
use
olympu
microscop
magnif
